The effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes

Medical Science Monitor

Volumn 24, Issue , 2018, Pages 9019-9025

  Karakurt, Yucel ^a   Ucak, Turgay ^a   Taslı, Gamze ^a   Agcayazı, Burcu ^b   İcel, Erel ^b   Yılmaz, Hayati ^b  

^a ERZINCAN UNIVERSITY   (Turkey)

^b Erzincan Mengucekgazi Education and Research Hospital   (Turkey)

Author keywords

Axial length, eye; Intraocular pressure; Intravitreal injections

Indexed keywords

AFLIBERCEPT; DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGE RELATED MACULAR DEGENERATION; ANGIOGRAPHY; ANTERIOR EYE CHAMBER DEPTH; ARTICLE; BIOMETRY; BRANCH RETINAL VEIN OCCLUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; EYE AXIS LENGTH; FEMALE; FUNDUS FLUORESCEIN ANGIOGRAPHY; HIGH RISK PATIENT; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; RISK FACTOR; THERAPY EFFECT; TONOMETRY; VEIN THROMBOSIS; AGED; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; IMMUNOLOGY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; POSTOPERATIVE CARE; PROCEDURES; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DEXAMETHASONE; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85058591515     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.910923     Document Type: Article

References (32)

1. CATT Research Group, Martin DF, Maguire MG, Ying GS et al: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med, 2011; 364: 1897–908
2. Lee YJ, Park HJ, Lee TG et al: Primary combined photodynamic therapy and intravitreal bevacizumab injection for neovascular age-related macular degeneration. J Korean Ophthalmol Soc, 2010; 51(1): 35–41
3. Sampat KM, Garg SJ: Complications of intravitreal injections. Curr Opin Ophthal, 2010; 21(3): 178–83
4. Hollands H, Wong J, Bruen R et al: Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol, 2007; 42(6): 807–11
5. Kim JE, Mantravadi AV, Hur EY, Covert DJ: Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol, 2008, 146(6): 930–34.e1
6. Falkenstein IA, Cheng L, Freeman WR: Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina, 2007; 27(8): 1044–47
7. Kim YJ, Sung KR, Lee KS et al: Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol, 2014; 157: 1266–71.e1
8. Mazzulla DA, Hariprasad SM, Jager RD, Mieler WF: Short-term intraocular pressure trends after intravitreal injection of bevacizumab (avastin). Retin Cases Brief Rep, 2008; 2: 234–35
9. Hoang QV, Mendonca LS, Della Torre KE et al: Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology, 2012; 119(2): 321–26
10. Segal O, Ferencz JR, Cohen P et al: Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Isr Med Assoc J, 2013; 15: 352–55
11. Kotliar K, Maier M, Bauer S et al: Effect of intravitreal injections and volume changes on intraocular pressure: Clinical results and biomechanical model. Acta Ophthalmol Scand, 2007; 85: 777–81
12. Frenkel MP, Haji SA, Frenkel RE: Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol, 2010; 128: 1523–27
13. Omay E, Elgin U, Sen E, Yilmazbas P: The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness. Int Ophthalmol, 2016; 36(5): 665–70
14. Trehan HS, Kaushik J, Rangi A et al: Anterior segment changes on ultrasound biomicroscopy after intravitreal anti vascular endothelial growth factor injection. Med J Armed Forces India, 2017; 73(1): 58–64
15. Lee JW, Park H, Choi JH et al: Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol, 2016; 16: 69
16. Lim HB, Kim MS, Jo YJ, Kim JY: Short-term visual acuity and intraocular pressure changes and their correlation after anti-vascular endothelial growth factor injection. Ophthalmologica, 2016; 236(1): 36–42
17. Pece A, Allegrini D, Montesano G, Dimastrogiovanni AF: Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: A randomized study. Clin Ophthalmol, 2016; 10: 1131–38
18. Hollands H, Wong J, Bruen R, Campbell RJ et al: Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol, 2007; 42(6): 807–11
19. Cacciamani A, Oddone F, Parravano M et al: Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol, 2013; 57(1): 63–67
20. Hoang QV, Jung JJ, Mrejen S, Freund KB: Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy. Retina, 2014; 34(3): 519–24
21. Fuest M, Kotliar K, Walter P, Plange N: Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry. Ophthalmic Physiol Opt, 2014; 34: 438–44
22. Bakri SJ, Beer PM: The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging, 2003; 34: 386–90
23. Sniegowski M, Mandava N, Kahook MY: Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J, 2010; 4: 28–29
24. Chang-Lin JE, Attar M, Acheampong AA et al: Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci, 2011; 52: 80–86
25. Edelman JL: Differentiated intraocular glucocorticoids. Ophthalmologica, 2010; 224: 25–30
26. Thakur A, Kadam R, Kompella UB: Trabecular meshwork and lens partitioning of corticosteroids: Implications for elevated intraocular pressure and cataracts. Arch Ophthalmol, 2011; 129: 914–20
27. Srinivasan R, Sharma U, George R et al., Sankara Nethralaya Vitreoretinal Study Group (SNVR Study Group): Intraocular pressure changes after dexamethasone implant in patients with glaucoma and steroid responders. Retina, 2017 [Epub ahead of print]
28. Alagoz N, Alagoz C, Yılmaz I et al: Immediate intraocular pressure changes following intravitreal dexamethasone implant. J Ocul Pharmacol Ther, 2016; 32: 44–49
29. Papadia M, Misteli M, Jeannin B, Herbort CP: The influence of anti-VEGF therapy on present day management of macular edema due to and CRVO: A longitudinal analysis on visual function, injection time interval and complications. Int Ophthalmol, 2014; 34(6): 1193–201
30. Wen JC, Reina-Torres E, Sherwood JM et al: Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci, 2017; 58(3): 1893–98
31. Quigley HA, Anderson DR: Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci, 1977; 16: 640–44
32. Michelson G, Groh MJ, Langhans M: Perfusion of the juxtapapillary retina and optic nerve head in acute ocular hypertension. Ger J Ophthalmol, 1996; 5(6): 315–21